Long-term Risk of Heart Failure and Other Adverse Cardiovascular Outcomes in Granulomatosis With Polyangiitis: A Nationwide Cohort Study

被引:6
|
作者
Sun, Guoli [1 ]
Yafasova, Adelina [1 ]
Baslund, Bo [2 ]
Faurschou, Mikkel [2 ]
Schou, Morten [3 ]
Shams-Eldin, Abdulrahman N. [1 ]
Kristensen, Soren Lund [1 ]
Weeke, Peter E. [1 ]
Torp-Pedersen, Christian [4 ]
Fosbol, Emil L. [1 ]
Kober, Lars [1 ]
Butt, Jawad H. [1 ]
机构
[1] Copenhagen Univ Hosp, Rigshosp, Dept Cardiol, Blegdamsvej 9, DK-2100 Copenhagen, Denmark
[2] Copenhagen Univ Hosp, Rigshosp, Dept Rheumatol, Copenhagen, Denmark
[3] Copenhagen Univ Hosp, Herlev Gentofte Hosp, Dept Cardiol, Copenhagen, Denmark
[4] Nordsjaellands Hosp, Dept Cardiol, Hillerod, Denmark
关键词
cardiovascular diseases; granulomatosis with polyangiitis; heart failure; CARDIAC INVOLVEMENT; EOSINOPHILIC GRANULOMATOSIS; MYOCARDIAL-INFARCTION; WEGENERS; MORTALITY; PATIENT; STROKE; PRESCRIPTION; VASCULITIS;
D O I
10.3899/jrheum.210677
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To examine the long-term rates of heart failure (HF) and other adverse cardiovascular (CV) outcomes in a nationwide cohort of patients diagnosed with granulomatosis with polyangiitis (GPA) compared with the general population. Methods. Using Danish nationwide registries, patients with newly diagnosed GPA were identified and matched 1:4 by age, sex, and comorbidities with subjects from the general population. Outcomes were compared using Cox regression. Due to violation of the proportional hazard assumption, landmark analyses for the first year and from 1 year were performed. Results. Of the 1923 patients with GPA, 1781 patients (median age 59 yrs, 47.9% men) were matched with 7124 subjects from the general population. The median follow-up was 6.4 years. The absolute 10-year risk of HF was 6.8% (95% CI 5.5-8.2%) for patients with GPA and 5.9% (5.3-6.6%) for the general population. During the first year after diagnosis, GPA was associated with a significantly higher rate of HF (hazard ratio [HR] 3.60, 95% CI, 2.28-5.67) and other adverse outcomes, including atrial fibrillation/flutter (HR 6.50, 95% CI 4.43-9.55) and ischemic stroke (HR 3.24, 95% CI 1.92-5.48), compared with the general population. After the first year, GPA was not associated with higher rates of HF or other CV outcomes compared with the general population, except atrial fibrillation/flutter (HR 1.38, 95% CI 1.12-1.70). Conclusion. During the first year after diagnosis, the rates of HF and other CV outcomes were higher in patients with GPA compared with the general population. However, after the first year, the rates of HF and other CV outcomes, except atrial fibrillation/flutter, were similar to those in the general population.
引用
收藏
页码:291 / 298
页数:8
相关论文
共 50 条
  • [21] Increased Long-Term Cardiovascular Risk After Total Hip Arthroplasty A Nationwide Cohort Study
    Gordon, Max
    Rysinska, Agata
    Garland, Anne
    Rolfson, Ola
    Aspberg, Sara
    Eisler, Thomas
    Garellick, Goran
    Stark, Andre
    Hailer, Nils P.
    Skoldenberg, Olof
    MEDICINE, 2016, 95 (06) : 1 - 7
  • [22] Long-Term Risk of VTE in Sarcoidosis A Nationwide Cohort Study
    Yafasova, Adelina
    Fosbl, Emil L.
    Gustafsson, Finn
    Krintel, Sophine B.
    Kristensen, SOren L.
    Schou, Morten
    Petersen, Jeppe K.
    Sun, Guoli
    Rossing, Kasper
    Doi, Seiko N.
    Kober, Lars
    Butt, Jawad H.
    CHEST, 2024, 166 (01) : 136 - 145
  • [23] Long-term Outcome of Airway Stenosis in Granulomatosis With Polyangiitis (Wegener Granulomatosis) An Observational Study
    Del Pero, Marcos Martinez
    Jayne, David
    Chaudhry, Afzal
    Sivasothy, Pasupathy
    Jani, Piyush
    JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2014, 140 (11) : 1038 - 1044
  • [24] Remission induction therapies and long-term outcomes in granulomatosis with polyangiitis and microscopic polyangiitis: real-world data from a European cohort
    Stefan Krämer
    Kristian Vogt
    Theresa Maria Schreibing
    Martin Busch
    Tobias Schmitt
    Raoul Bergner
    Sebastian Mosberger
    Thomas Neumann
    Thomas Rauen
    Rheumatology International, 45 (1)
  • [25] Long-term outcomes of rituximab (RTX) therapy in recurrent Granulomatosis with Polyangiitis (GPA)
    Gawryluk, Dariusz
    Fijolek, Justyna
    Wiatr, Elzbieta
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [26] Clinical Manifestations and Long-Term Outcomes of Eosinophilic Granulomatosis With Polyangiitis in North America
    Doubelt, Irena
    Cuthbertson, David
    Carette, Simon
    Chung, Sharon A.
    Forbess, Lindsy J.
    Khalidi, Nader A.
    Koening, Curry L.
    Langford, Carol
    McAlear, Carol A.
    Moreland, Larry W.
    Monach, Paul A.
    Seo, Philip
    Specks, Ulrich
    Spiera, Robert F.
    Springer, Jason M.
    Sreih, Antoine G.
    Warrington, Kenneth J.
    Merkel, Peter A.
    Pagnoux, Christian
    ACR OPEN RHEUMATOLOGY, 2021, 3 (06) : 404 - 412
  • [27] The severe long-term outcomes of 'non-severe' eosinophilic granulomatosis with polyangiitis
    Berti, Alvise
    RHEUMATOLOGY, 2019, 58 (12) : 2081 - 2082
  • [28] METABOLOMIC INVESTIGATION OF LONG-TERM RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN A COMMUNITY-BASED COHORT (HEART SCORE) STUDY
    Emechebe, Nnadozie
    Anh Thy Nguyen
    Linh Duong
    Kip, Kevin
    Masri, Ahmad
    Erqou, Sebhat
    Reis, Steven
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (09) : 1835 - 1835
  • [29] Metformin in pregnancy and risk of adverse long-term outcomes: a register-based cohort study
    Brand, Kerstin M. G.
    Saarelainen, Laura
    Sonajalg, Jaak
    Boutmy, Emmanuelle
    Foch, Caroline
    Vaarasmaki, Marja
    Morin-Papunen, Laure
    Schlachter, Judith
    Hakkarainen, Katja M.
    Korhonen, Pasi
    BMJ OPEN DIABETES RESEARCH & CARE, 2022, 10 (01)
  • [30] Estimating Risk of Cardiovascular Disease Among Long-Term Colorectal Cancer Survivors: A Nationwide Cohort Study
    Jeong, Seogsong
    Lee, Gyeongsil
    Choi, Seulggie
    Kim, Kyae Hyung
    Chang, Jooyoung
    Kim, Sung Min
    Kim, Kyuwoong
    Son, Joung Sik
    Cho, Yoosun
    Park, Sang Min
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 8